L3VLUP
ProSign in

ABT · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ABTJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ABT
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterABTJNJ
Q3 202027 holders, $24.7bn30 holders, $26.2bn
Q4 202029 holders, $24.8bn32 holders, $26.6bn
Q1 202131 holders, $27.6bn31 holders, $25.3bn
Q2 202129 holders, $26.5bn37 holders, $25.6bn
Q3 202134 holders, $25.4bn40 holders, $24.1bn
Q4 202128 holders, $29.2bn33 holders, $25.2bn
Q1 202234 holders, $24.2bn35 holders, $28.2bn
Q2 202233 holders, $21.5bn33 holders, $26.9bn
Q3 202230 holders, $18.8bn36 holders, $25.4bn
Q4 202225 holders, $20.6bn35 holders, $27.6bn
Q1 202332 holders, $19.2bn42 holders, $24.5bn
Q2 202327 holders, $20.4bn38 holders, $25.0bn
Q3 202330 holders, $17.7bn37 holders, $18.9bn
Q4 202324 holders, $21.0bn31 holders, $19.0bn
Q1 202427 holders, $20.6bn32 holders, $19.7bn
Q2 202437 holders, $16.8bn35 holders, $20.4bn
Q3 202428 holders, $17.7bn28 holders, $22.3bn
Q4 202422 holders, $16.6bn37 holders, $20.4bn
Q1 202528 holders, $20.9bn32 holders, $20.5bn
Q2 202526 holders, $21.1bn31 holders, $18.4bn
Q3 202520 holders, $21.3bn32 holders, $23.7bn
Q4 202525 holders, $20.6bn29 holders, $27.8bn
Q1 202635 holders, $19.1bn34 holders, $35.6bn
Q2 202636 holders, $15.8bn33 holders, $39.1bn
ABT

Abbott Laboratories

Holders
25
Reported value
$20.6bn
Buyers
18
Sellers
18

Breadth 0 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ABT (8)

Citadel Advisors LLC, Harris Associates LP, Holocene Advisors LP, Polen Capital Management LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Tudor Investment Corp, Walleye Capital LLC

Only JNJ (12)

Brevan Howard Capital Management LP, Element Capital Management LLC, Freestone Grove Partners LP, Hudson Bay Capital Management LP, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Millennium Management LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, Two Sigma Advisers LP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →